Cyberlux and TrellisWare Partner to Deliver Cutting-Edge FPV Anti-Jam Capability on New UAS Platform

RESEARCH TRIANGLE PARK, N.C., May 07, 2025--(BUSINESS WIRE)--Cyberlux Corporation (OTC: CYBL), a leading provider of tactical unmanned aerial systems and advanced defense technologies, is proud to announce its strategic partnership with TrellisWare Technologies, Inc. integrating TrellisWare's new low-latency, anti-jam waveform for uncrewed systems into Cyberlux's latest heavy-lift Group 1 rotary-wing UAS platform.
This partnership marks a significant step forward in enabling First Person View (FPV) operations in contested electromagnetic environments. When bridged to TrellisWare's battle-proven TSM® waveform, the new integration delivers resilient, low-latency FPV flight capabilities while maintaining seamless connectivity to existing deployed TSM networks—a critical advantage for U.S. and allied forces operating in GPS- and RF-denied areas.
Cyberlux's new UAS platform, purpose-built for the U.S. Special Operations community, now combines heavy-payload capacity and long-duration flight performance with uncompromised situational awareness through this advanced waveform. The result is a mission-flexible, EW-resilient system that enables precise FPV operation in the most demanding operational environments.
"TrellisWare's newly released uncrewed systems waveform for FPV operation, unveiled at AUVSI last year, is a game-changer," said Mark Schmidt, CEO of Cyberlux Corporation. "By integrating this technology into our next-generation UAS, we're not only expanding the tactical capability of our platforms—we're ensuring our systems remain fully interoperable and battlefield-ready."
This collaboration reinforces Cyberlux's commitment to delivering unmatched innovation in unmanned systems, C5ISR solutions, and integrated defense technologies.
To learn more, visit www.cyberlux.com.
About Cyberlux Corporation
Cyberlux Corporation (OTC: CYBL) delivers innovative defense technology platforms across unmanned aerial systems (UAS), tactical communications, and global mission services. For over 20 years, Cyberlux has supported the U.S. Department of Defense and allied military programs with cutting-edge solutions that enable mission success across dynamic operating environments.
About TrellisWare Technologies, Inc.
TrellisWare Technologies is a global leader in resilient communications technology, delivering advanced waveform innovations for military and commercial applications. With its TSM® waveform at the core of many mission-critical systems, TrellisWare enables robust, scalable, and secure connectivity in complex and contested environments. TrellisWare's solutions empower forces with seamless communication, situational awareness, and operational success in the most demanding scenarios.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

9 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Business Insider

12 hours ago

• Business Insider

Inside SoftBank's $1 Trillion AI Gamble: What It Means for SFTBY Investors

SoftBank Group (SFTBY) is exploring a $1 trillion plan to build a massive AI and robotics manufacturing hub in Arizona. The project, known as 'Project Crystal Land,' is still in its early planning stages but aims to produce semiconductors and industrial robots at scale. The goal is to expand U.S. manufacturing capacity in advanced technologies and reduce reliance on imports. Confident Investing Starts Here: TSMC Is a Potential Partner The initiative is being led by CEO Masayoshi Son and modeled after Shenzhen's high-tech zones in China. According to reports, SoftBank is in talks with the Trump administration, including Commerce Secretary Howard Lutnick, about possible tax incentives and regulatory support. The company is also reaching out to tech giants like Taiwan Semiconductor Manufacturing (TSM) and Samsung Electronics (SMSN) to participate. So far, TSM has not confirmed any commitment beyond its existing $165 billion investment in U.S. chip production. SoftBank may also involve some of its Vision Fund portfolio companies by setting up production facilities inside the new complex. The project's success will depend on a combination of government backing, industry partnerships, and financing. SoftBank has already taken similar steps with the $500 billion Stargate AI infrastructure initiative, which includes partners like Oracle (ORCL), OpenAI, and MGX. For now, Project Crystal Land is more concept than construction site. But it reflects SoftBank's continued push to expand its presence in U.S. tech and AI infrastructure. What Is SFTBY Stock's Smart Score? SoftBank currently holds a Smart Score of 3, landing it in the 'Underperform' zone. While analysts rate the stock a 'Hold' with an average price target of $32.20, market sentiment is mixed. Fundamentals indicate a 10.28% return on equity, but a 2.50% decline in asset growth over the past year.

Yahoo

2 days ago

• Yahoo

Chip equipment stocks fall after US plans to revoke China waivers

-- Taiwan Semiconductor Manufacturing (NYSE:TSM) stock fell 2%, Lam Research (NASDAQ:LRCX) shares tumbled 5%, and Applied Materials (NASDAQ:AMAT) dropped 4% following reports that a U.S. official plans to revoke technology waivers for chipmakers operating in China. Jeffrey Kessler, who leads the export controls unit at the Commerce Department, has informed major semiconductor manufacturers including Taiwan Semiconductor Manufacturing, Samsung Electronics (KS:005930), and SK Hynix of his intention to cancel blanket waivers that currently allow them to ship American chip-making equipment to their factories in China without applying for separate licenses each time, according to the Wall Street Journal. The potential policy change is reportedly part of the Trump administration's broader efforts to restrict critical U.S. technology from going to China. If implemented, the move could create significant disruption both diplomatically and economically, coming shortly after the U.S. and China established a trade truce in London. White House officials have stated that this action would not represent a new trade escalation but would instead align the licensing system for chip equipment with China's existing system for rare-earth materials. They added that the U.S. and China continue to make progress on completing their London agreement. "Chip makers will still be able to operate in China. The new enforcement mechanisms on chips mirror licensing requirements that apply to other semiconductor companies that export to China and ensure the United States has an equal and reciprocal process," a Commerce Department spokesman said. The semiconductor equipment sector is particularly vulnerable to changes in U.S.-China trade policy, as many companies rely on access to the Chinese market for significant portions of their revenue. Related articles Chip equipment stocks fall after US plans to revoke China waivers QXO won't participate in bidding war for GMS - source Reddit in talks to use Sam Altman's World ID for user verification - Semafor